根据 NICE 和 GOLD 建议与英国当前临床实践对 COPD 治疗进行成本-效果分析。

Cost-consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK.

机构信息

Maverex Ltd, Newcastle-upon-Tyne, UK

Former employees of, Boehringer Ingelheim Ltd, Bracknell, UK.

出版信息

BMJ Open. 2022 Jun 3;12(6):e059158. doi: 10.1136/bmjopen-2021-059158.

Abstract

OBJECTIVES

The objective of this study was to model the clinical and economic impact of adapting current clinical practice in the management of patients with chronic obstructive pulmonary disease (COPD) to treatment according to national and international guideline recommendations.

DESIGN

Treatment mapping was undertaken to hypothetically redistribute patients from current clinical practice, representing actual prescribing patterns in the UK, to an alternative recommendation-based treatment scenario, representing prescribing in accordance with either National Institute for Health and Care Excellence (NICE) guidance [NG115] or Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 strategy.

SETTING

Primary care practices in the UK (1-year time horizon).

PARTICIPANTS

Adults with COPD undergoing long-acting inhaler maintenance therapy in the UK (N=1 067,531).

INTERVENTIONS

Inhaler maintenance therapy.

OUTCOME MEASURES

Costs and clinical outcomes (type of treatment, rates of moderate and/or severe exacerbations, and mild-to-moderate and/or severe pneumonia events) were modelled for the two alternative pathways.

RESULTS

Compared with current clinical practice, treating patients according to NICE guidance resulted in an estimated annual reduction in expenditure of £46.9 million, and an estimated annual reduction in expenditure of over £43.7 million when patients were treated according to GOLD 2020 strategy. Total cost savings of up to 8% annually could be achieved by treatment of patients according to either of these recommendations. Cost savings arose from a reduction in the rates of pneumonia, with an associated decrease in costs associated with antibiotic use and hospitalisation. Savings were achieved overall despite a small increase in the rate of exacerbations due to the redistribution of certain patients currently undergoing triple inhaled therapy to therapies not containing inhaled corticosteroids.

CONCLUSION

Redistribution of patients with COPD from current clinical practice to treatment according to published recommendations would provide substantial cost savings over the first year.

摘要

目的

本研究旨在建立模型,以评估根据当前慢性阻塞性肺疾病(COPD)管理的临床实践来模拟治疗方案,使其适应国家和国际指南推荐,从而对临床和经济产生的影响。

设计

采用治疗映射法,将目前的临床实践中(代表英国的实际处方模式)的患者,假设重新分配到替代的基于推荐的治疗方案中,即根据英国国家卫生与保健优化研究所(NICE)指南[NG115]或全球慢性阻塞性肺疾病倡议(GOLD)2020 策略进行处方。

设置

英国的初级保健实践(1 年时间范围)。

参与者

在英国接受长效吸入维持治疗的 COPD 成年患者(N=1067531)。

干预措施

吸入维持治疗。

结果

与当前的临床实践相比,根据 NICE 指南治疗患者预计每年可节省 4690 万英镑的支出,而根据 GOLD 2020 策略治疗患者预计每年可节省超过 4370 万英镑的支出。根据这两种建议中的任何一种治疗患者,每年最多可节省 8%的总成本。成本节省来自肺炎发生率的降低,从而降低了抗生素使用和住院相关的成本。尽管由于某些目前接受三联吸入治疗的患者被重新分配到不含吸入性皮质类固醇的治疗方案中,导致恶化率略有增加,但总体上仍实现了节省。

结论

将 COPD 患者从当前的临床实践重新分配到根据已发表的建议进行治疗,将在第一年提供大量的成本节省。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2146/9171279/12516de42079/bmjopen-2021-059158f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索